Fas Ligand/TNFSF6 Antibody [Alexa Fluor® 647]

• Reactivity: Hu
• Applications: WB, Flow, IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 647

Fas Ligand/TNFSF6 Antibody [Alexa Fluor® 647] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant human Fas Ligand/TNFSF6
  Pro134-Leu281
  Accession # Q53ZZ1
• Specificity: Detects human Fas Ligand in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant mouse Fas Ligand is observed, approximately 7% cross-reactivity with recombinant rat Fas Ligand and recombina
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunohistochemistry
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Fas Ligand/TNFSF6 Antibody [Alexa Fluor® 647]

• apoptosis (APO-1) antigen ligand 1
• Apoptosis antigen ligand
• APT1LG1CD95L
• APTL
• CD178 antigen
• CD178
• CD95L
• CD95-L
• Fas antigen ligand
• Fas ligand (TNF superfamily, member 6)
• Fas Ligand
• FASLCD95 ligand
• FASLG
• TNFSF6
• TNFSF6FasL
• tumor necrosis factor (ligand) superfamily, member 6
• tumor necrosis factor ligand superfamily member 6

Background

Fas Ligand (FasL), also known as CD178, CD95L, or TNFSF6, is a 40 kDa type II transmembrane member of the TNF superfamily of proteins. Its ability to induce apoptosis in target cells plays an important role in the development, homeostasis, and function of the immune system (1). Mature human Fas Ligand consists of a 179 amino acid (aa) extracellular domain (ECD), a 22 aa transmembrane segment, and a 80 aa cytoplasmic domain (2). Within the ECD, human Fas Ligand shares 81% and 78% aa sequence identity with mouse and rat Fas Ligand, respectively. Both mouse and human Fas Ligand are active on mouse and human cells (2, 3). Fas Ligand is expressed on the cell surface as a nondisulfide-linked homotrimer on activated CD4⁺ Th1 cells, CD8⁺ cytotoxic T cells, and NK cells (1). Fas Ligand binding to Fas/CD95 on an adjacent cell triggers apoptosis in the Fas‑expressing cell (2, 4). Fas Ligand also binds DcR3 which is a soluble decoy receptor that interferes with Fas Ligand-induced apoptosis (5). Fas Ligand can be released from the cell surface by metalloproteinases as a 26 kDa soluble molecule which remains trimeric (6, 7). Shed Fas Ligand retains the ability to bind Fas, although its ability to trigger apoptosis is dramatically reduced (6, 7). In the absence of TGF‑ beta , however, Fas Ligand/Fas interactions instead promote neutrophil-mediated inflammatory responses (3, 8). Fas Ligand itself transmits reverse signals that costimulate the proliferation of freshly antigen-stimulated T cells (9). Fas Ligand-induced apoptosis plays a central role in the development of immune tolerance and the maintance of immune privileged sites (10). This function is exploited by tumor cells which evade immune surveillance by upregulating Fas Ligand to kill tumor infiltrating lymphocytes (8, 11). In gld mice, a Fas Ligand point mutation is the cause of severe lymphoproliferation and systemic autoimmunity (12, 13).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.